Home' Australian Pharmacist : Australian Pharmacist January 2017 Contents Australian Pharmacist January 2017 I ©Pharmaceutical Society of Australia Ltd.
Items in the Product news section are prepared from information provided by the companies named in each item. They are included for the information of PSA members. It is up to
the individual member to use their professional judgment to decide on the merit or otherwise of each product mentioned. PSA neither endorses nor confirms claims made in the
items. (Where provided by the company references citing evidence are included with the items.)
Australian Pharmacist is a professional journal. It will carry only advertising which is likely to be of interest to all pharmacists and which does not reflect unfavourably directly or by
implication on the pharmacy profession or the professional practice of pharmacy. Advertising which does not comply with this policy will be refused. It is the responsibility of the
advertisers to comply with the relevant Commonwealth and State law. Advertising does not constitute an endorsement by PSA of the claims, products or services.
AUSTRALIA’S MOST CLOSELY READ PHARMACY JOURNAL
OC TOBER 2 016
PRINT POST APPROVED
The evidence: Omega-3 and
- 6 fatty acids, and turmeric
Old drug new indication
Propanolol for forgetting
the fear after trauma?
The quest for
Australia’s highest rated
TO ADVERTISE CONTACT
email@example.com | Jonathon Tremain 02 9988 4689 | Amanda Bennetts 0402 055 022 | Jeff Johnston 02 9871 5520
Community pharmacists value and use Australian Pharmacist for six of their top
seven information needs.
Most credible for patient counselling, S2 S3 medicines, professional services,
clinical information, prescription medicines and CPD (education).
Pharmacy Publications & Media 2016. Competitive Advantage Research, July 2016
Bacterial imbalances of the
vagina and urogenital tract can
affect the health of the vaginal
environment, and are often
the cause of general vaginal
discomfort, with many women
experiencing imbalance at some
point in their lives. UltraBiotic
FEMI+ may help to remedy this imbalance,
and encourage the growth of good bacteria in
the urogenital tract according to BioCeuticals.
UltraBiotic FEMI+ contains a combination of six
probiotics and Lactobacillus plantarum which,
when delivered vaginally, may increase numbers
of good bacteria.
BioCeuticals Education Manager Belinda
Reynolds said imbalances in vaginal microflora
were surprisingly common, and could be caused
by fluctuations in oestrogen levels (during
menopause, pregnancy and different times of
the menstrual cycle), sexual activity and hygiene
Probiotics can be delivered vaginally or orally,
however probiotics delivered in a pessary form
(a capsule inserted locally into the vagina)
may work more quickly than those taken orally
as oral probiotics need to pass through the
gastrointestinal tract first before reaching the
Australians living with progressive, locally advanced or metastatic
symptomatic radioactive iodine refractory differentiated thyroid cancer
(RAI refractory DTC) now have access to Lenvima (lenvatinib). It was listed
on the Pharmaceutical Benefits Scheme (PBS) from 1 December. RAI
refractory DTC is a difficult to treat condition with a poor prognosis and
Lenvima is a new option for patients.
It is the first and only therapy for RAI
refractory DTC to receive reimbursement from the PBS.
Lenvatinib is a multiple receptor tyrosine kinase (RTK) inhibitor that
inhibits the kinase activities of vascular endothelial growth factor (VEGF)
receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), in addition
to other proangiogenic and oncogenic pathway-related RTKs including
fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4, the platelet
derived growth factor (PDGF) receptor PDGFRα, KIT, and RET.
Lenvima is registered in Australia by the Therapeutic Goods Authority
(TGA) for the treatment of patients with progressive locally advanced or
metastatic, differentiated thyroid cancer (DTC) refractory to radioactive
Approximately 2,500 people in Australia are estimated to be diagnosed
with thyroid cancer each year. Although thyroid cancer is rare, incidence
rates have risen for both males and females over the past two decades.
Females are three times more likely than males to develop thyroid cancer,
making it the eighth leading cause of cancer in females in Australia.
1. Shah JP, et al. New and emerging therapeutic options for thyroid carcinoma. At: www.ncbi.nlm.nih.gov/
pubmed/25856096 Accessed: Dec 2016.
2. Lenvima Product Information, Mar 2016.
In the December issue Prescobix was reported as being PBS listed from
October 2017. This should have been October 2016.
Links Archive Australian Pharmacist December2016 Navigation Previous Page Next Page